KRAS and neoplasm: Comparing patients with a high tumor burden [progressive disease (PD) or treatment‐naïve] to those with a low tumor burden (SD, PR or CR), a significant difference in the ctDNA fraction emerged for BRAF (22.2% vs 4.7%, P < 0.05), while no significant differences were observed for KRAS (3.0% vs 2.3%, P = 0.63) and NRAS (0.09% vs 0.23%, P = 0.10).